Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs Quantum Computing Inc (QUBT) Price & Performance

BioNTech SE - ADRTrade
Quantum Computing IncTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs Quantum Computing Inc — how do they compare? BioNTech SE - ADR trades at $93.13 (market cap $23.31B), while Quantum Computing Inc trades at $8.94 (market cap $2.03B). The key difference: BioNTech SE - ADR is far larger — about 11.5× Quantum Computing Inc's market cap, and BioNTech SE - ADR is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals.

BNTXQUBT
Market Cap
$23.31B$2.03B
Sector
HealthTechnology
52-Week High
$119.34$24.62
52-Week Low
$83.89$6.31
Enterprise Value
$6.60B$1.09B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.

The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.

Quantum Computing Inc

Quantum Computing Inc. (QUBT) trades at $9.07, up 1.57% with bearish technical signals despite recent revenue growth. The company reported Q2 2026 revenue of $5.6 million, a significant increase from prior periods, though profitability remains challenged with negative margins. Analyst consensus is bullish with a $18.50 price target, while institutional interest grows with recent purchases by Amundi and Bank of New York Mellon.

QUBT presents high-risk, high-reward potential with strong revenue growth from photonics sales but faces execution risks and negative profitability. The stock's 75% buy rating from analysts suggests upside potential, though investors must weigh the speculative nature against substantial cash reserves and expanding manufacturing capabilities.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About Quantum Computing Inc

Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.

Read more on QUBT